Chris Peetz is a co-founder of Mirum and serves as chief executive officer.

Chris has been an entrepreneur-in-residence at Frazier Healthcare Partners since May 2017. Prior to joining Mirum, Chris served as the chief executive officer of Flashlight Therapeutics, Inc. From May 2014 to December 2016, he served as chief financial officer and head of corporate development at Tobira, which was acquired by Allergan plc, in November 2016. Prior to joining Tobira, Chris served as vice president, finance and corporate development of Jennerex Biotherapeutics. Prior to Jennerex, Chris held various positions at Onyx Pharmaceuticals, Inc. (now Amgen Inc.), including corporate strategy, marketing, product lifecycle management, and financial planning. Prior to Onyx, Chris provided merger and acquisition advisory services at LaSalle Corporate Finance, a part of ABN AMRO, and held positions at Abgenix Inc. and Solazyme Inc. He also serves as a member of the board of directors of Alpine Immune Sciences, Inc., a public immunotherapy company, since April 2018.

Chris received an M.B.A. from Stanford Graduate School of Business and a B.S.B.A. in Finance, International Business and French from Washington University in St. Louis.

Erin Campany joined Mirum in 2019 and serves as senior vice president of human resources, overseeing people management and organizational development, as well as HR programs and culture at the company.

Erin brings more than 20 years of human resources leadership experience focused on building strong company cultures, developing strategies to positively impact organizational climate and dynamics, and ensuring a competitive and compelling overall employee value proposition. Prior to Mirum, Erin served as head of human resources at Immune Design. From 2013-2017, she oversaw Global Human Resources for Biotie Therapeutics (now Acorda Therapeutics) and also served an integral role during the company’s integration following its acquisition by Acorda. Erin held similar roles at VaxGen, Inc. and Exelixis and served as a human resources consultant to biotechnology companies throughout the Bay Area.

Erin has a bachelor’s degree in industrial psychology from San Jose State University.

Eric Bjerkholt joined Mirum as chief financial officer in September 2023. Eric joined Mirum from Chinook Therapeutics, Inc. where served as chief financial officer overseeing financial reporting, planning and budgeting, internal controls, investor relations, facilities, and information technology functions. Prior to Chinook, he served as CFO at Aimmune Therapeutics, Inc. Before Aimmune, Eric worked at Sunesis Pharmaceuticals, Inc., IntraBiotics Pharmaceuticals, Inc., LifeSpring Nutrition, Inc., and Age Wave, LLC. Prior to joining industry, Eric spent nearly a decade in healthcare investment banking at J.P. Morgan & Company, Inc. He is currently a member of the board of directors of CalciMedica, Inc., Cerus Corporation and Surrozen, Inc.

Eric holds an MBA from Harvard Business School and a Cand.Oecon degree from the University of Oslo in Norway.

Ian Clements, Ph.D., has served as chief financial officer since January 2020. Prior to this he served as senior vice president finance and communications and our principal financial and accounting officer since March 2019.

Prior to joining Mirum, Ian served as vice president of investor relations at Dermira, Inc. from May 2017 to March 2019. Ian served as vice president, investor relations and corporate communications at Tobira from July 2015 to December 2016. Prior to that, he was head of investor relations and corporate communications at Avanir Pharmaceuticals from 2011 to June 2015. Ian has also held leadership positions at Sequenom, a genetic analysis and diagnostics company, and The Trout Group, where he managed west coast operations for life sciences investor relations.

Ian received a Ph.D. in chemistry from the University of Manchester, an M.B.A. from the Open University in the United Kingdom and a B.Sc. in chemistry from Staffordshire University.

Jean-Luc Girardet joined Mirum in 2022 and serves as senior vice president of technical operations, overseeing chemistry, manufacturing, and controls (CMC) and clinical supply chain.  Jean-Luc brings more than 25 years of operational and technical experience in the biotech and pharmaceutical industry.

Prior to joining Mirum, Jean-Luc served as senior vice president of pharmaceutical sciences at Brii Biosciences from inception (2018) to 2022. From 2007 to 2018, he worked at Ardea Biosciences, a member of the AstraZeneca Group, serving in a variety of executive leadership roles including vice president of pharmaceutical and translational sciences, leading the progression of Ardea’s internal discovery programs from concept to clinical development and eventually to approval.  He also led the CMC teams through clinical phases, FDA-approval and launch readiness of Zurampic® and Duzallo®.  Earlier in his career, Jean-Luc was at Valeant Pharmaceuticals, Ribapharm and ICN Pharmaceuticals.  

Jean-Luc completed a Postdoctoral Fellowship at the University of Michigan in Ann Arbor, Michigan, and he received a Ph.D. in Chemistry and a B.S. in Chemistry and Biochemistry from the University of Montpellier II, France. He co-authored more than 45 publications and book chapters and has been issued 35 U.S. patents.

Vinita Kumar is the senior vice president of quality, where she oversees GxP quality operations within clinical, laboratory, document control, training, and IT systems. She is also responsible for creating and implementing Mirum’s global inspection readiness strategies including oversight of the quality management system implementation and maintenance. Vinita brings more than 30 years of experience in building effective quality teams, successfully transitioning from early to late-stage programs and into commercialization. Prior to Mirum, she served in similar quality leadership roles at Corcept Therapeutics (2018-2021), Versartis (2016-2018), and Relypsa (2007-2016). Earlier in her career, she worked at numerous Bay Area–based biotech companies including Syntex/Roche in the areas of pre-formulation, analytical development, manufacturing, and quality control.

Vinita holds a Master of Science in physical organic chemistry from Southern Illinois University and both a Master of Science in organic chemistry and an undergraduate degree from Patna University.

Lara Longpre joined Mirum in 2018 as chief development officer with responsibility for program leadership, regulatory affairs, biometrics, and medical writing.  She brings more than 30 years of experience in the biopharmaceutical industry developing innovative and complex therapies.

Prior to Mirum, she served as chief operating officer at MedGenesis Therapeutix and Jennerex Biotherapeutics where she held responsibilities for program management, alliance management, clinical operations, technical operations, regulatory affairs, and quality assurance. She previously held several leadership roles in Contract Research Organizations including PRA International and CroMedica International where had responsibility for clinical operations and project management, global regulatory affairs, and proposals & contracts.

Lara received a Master of Medical Science degree from Harvard Medical School, an M.B.A. from Queen’s University in Ontario, Canada, and her undergraduate degree in biology from Cornell University.

Joanne Quan, MD joined Mirum in 2024 as chief medical officer with responsibility for clinical development, clinical operations, and safety. Joanne has nearly three decades of experience developing novel therapeutics, including those for rare diseases.

Prior to Mirum, she served as chief medical officer at Nuvig Therapeutics. From 2018-2021, she served in the same role at Modis Therapeutics, a company focused on rare genetic diseases (acquired by Zogenix, Inc., and subsequently, UCB),. Before Modis, she held clinical development leadership positions at Eiger Biopharmaceuticals, InterMune, Arena Pharmaceuticals, Bayhill Therapeutics, ALZA Corporation (Johnson and Johnson), Genentech, and PathoGenesis.

Joanne received a BA in molecular biology at the University of California, Berkeley and an MD at Stanford University School of Medicine. She completed a residency in internal medicine at Massachusetts General Hospital and a fellowship in pulmonary and critical care medicine at the University of Washington. 

Peter Radovich currently serves as president and chief operating officer at Mirum where he is responsible for commercial, corporate development, chemistry, manufacturing and controls (CMC), and supply chain. Peter joined Mirum in April 2020 as chief operating officer with more than 20 years of operational experience in the biopharmaceutical industry.

Prior to Mirum, he served as executive vice president, operations at Global Blood Therapeutics (GBT) from 2014 to 2020, responsible for technical operations, supply chain, program management and leadership, quality assurance, and commercial strategy and analytics functions. From 2006 to 2014, Peter worked at Onyx Pharmaceuticals, Inc. (now Amgen, Inc.) serving in a variety of roles including vice president, program leadership, as well as commercial and corporate strategy roles. Prior to Onyx, Peter held product marketing positions at Chiron Corporation (now Novartis AG).

Peter is also a board member at Rain Therapeutics Inc., a precision oncology company. Peter received an M.B.A. from Washington University in St. Louis and his undergraduate degree in biology and chemistry from Texas Christian University.

Paul Ross has served as the chief compliance officer for Mirum since April 2020, where he leads the company’s corporate and healthcare compliance efforts.

Paul brings to Mirum over 30 years of industry experience developing and overseeing compliance programs and commercial regulatory processes. Paul most recently served as the founding member of ComplianceStat LLC, providing strategic counsel to emerging pharmaceutical and biotech organizations on the implementation of compliance programs in preparation for commercial launch. Prior to ComplianceStat, he served as the chief compliance officer for Raptor Pharmaceuticals and Onyx Pharmaceuticals, where he oversaw compliance risk management, policy development, training, Sunshine Act reporting, and records management. Paul previously held leadership positions in compliance and regulatory affairs at Chiron, Intermune, and Pharmacia.